Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • News & Views
  • Published:

MULTIPLE SCLEROSIS

How common is active inflammation in progressive multiple sclerosis?

Nature Reviews Neurology volume 17, pages 463–464 (2021)Cite this article

Subjects

In patients with progressive multiple sclerosis, the presence of active inflammation is associated with improved efficacy of anti-inflammatory therapies. However, the frequency of active inflammation in this patient population is unknown, and is the subject of a new study.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

References

  1. Dangond, F. et al. Facing the urgency of therapies for progressive MS — a Progressive MS Alliance proposal. Nat. Rev. Neurol. 17, 185–192 (2021).

    Article  Google Scholar 

  2. Kappos, L. et al. Siponimod versus placebo in secondary progressive multiple sclerosis (EXPAND): a double-blind, randomised, phase 3 study. Lancet 391, 1263–1273 (2018).

    Article  CAS  Google Scholar 

  3. Hawker, K. et al. Rituximab in patients with primary progressive multiple sclerosis: results of a randomized double-blind placebo-controlled multicenter trial. Ann. Neurol. 66, 460–471 (2009).

    Article  CAS  Google Scholar 

  4. Montalban, X. et al. Ocrelizumab versus placebo in primary progressive multiple sclerosis. N. Engl. J. Med. 376, 209–220 (2017).

    Article  CAS  Google Scholar 

  5. Lublin, F. D. et al. The 2013 clinical course descriptors for multiple sclerosis: a clarification. Neurology 94, 1088–1092 (2020).

    Article  Google Scholar 

  6. Mathey, G. et al. Clinical and radiological activity of secondary progressive multiple sclerosis in a population-based cohort. Eur. J. Neurol. https://doi.org/10.1111/ene.14861 (2021).

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Mellen Center for Multiple Sclerosis Treatment and Research, Neurological Institute, Cleveland Clinic, Cleveland, OH, USA

    Robert J. Fox

Authors
  1. Robert J. Fox
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Robert J. Fox.

Ethics declarations

Competing interests

R.J.F. has received personal consulting fees from AB Science, Actelion, Biogen, Celgene, EMD Serono, Genentech, Immunic, Novartis, Sanofi and TG Therapeutics; served on advisory committees for Actelion, Biogen, Immunic, Novartis and Sanofi; and received clinical trial contract and research grant funding from Biogen, Novartis and Sanofi.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Fox, R.J. How common is active inflammation in progressive multiple sclerosis?. Nat Rev Neurol 17, 463–464 (2021). https://doi.org/10.1038/s41582-021-00518-4

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/s41582-021-00518-4

Search

Advanced search

Quick links

Nature Briefing: Translational Research

Sign up for the Nature Briefing: Translational Research newsletter — top stories in biotechnology, drug discovery and pharma.

Get what matters in translational research, free to your inbox weekly. Sign up for Nature Briefing: Translational Research